Therapeutic Targets
Therapeutic Targets - Related Videos
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
0 Views •
Cited by 2 •
2017
This protocol describes the in vitro comparison of two key functional characteristics of rituximab: target binding and complement-dependent cytotoxicity (CDC) induction. The methods were employed for a side-to-side comparison between reference rituximab and a rituximab biosimilar. These assays can be employed during biosimilar development or as a quality control in their production.
03:36
Pretargeted Radioimmunotherapy: A Method for Targeted Delivery of Therapeutic Radionuclides to Tumors
0 Views •
2023
This video describes the technique of pretargeted radioimmunotherapy or PRIT, in which immunoconjugates followed by radioligands are administered for treating tumors. This radioimmunotherapy reduces radiation doses to healthy tissues and utilizes radionuclides with very low half-lives incompatible with antibody-based vectors.
08:35
Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
0 Views •
Cited by 28 •
2012
Type B gelatin-based engineered nanovectors system (GENS) was developed for systemic gene delivery and transfection in the treatment of pancreatic cancer. By modification with epidermal growth factor receptor (EGFR) specific peptide on the surface of nanparticles, they could target on EGFR receptor and release plasmid under reducing environment, such as high intracellular glutathione concentrations.
08:43
Rat Model of Blood-brain Barrier Disruption to Allow Targeted Neurovascular Therapeutics
0 Views •
Cited by 9 •
2012
Blood-brain barrier disruption aids the delivery of certain drugs to the brain. Mannitol delivered intra-arterially shrinks cells surrounding blood vessels in order to physically disrupt the barrier.
07:36
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
0 Views •
Cited by 1 •
2020
Here we present a protocol to study the in vivo localization of antibodies in mice tumor xenograft models.
FAQs
A target’s distribution helps determine where an intervention can act and which tissues may experience its biological effects. Examining distribution connects molecular action with physiological function, while differences between healthy and diseased tissues can inform treatment precision. This information is especially relevant when designing therapies intended to limit disease progression without broadly disrupting normal biology.
Validation examines whether changing the activity of a candidate molecule, pathway, or disease mechanism produces a meaningful biological effect. The result should connect target modulation with restored physiological function or reduced disease progression. This step helps distinguish an association from a useful intervention point and guides later development of small molecules, biologics, or other treatments.
These target classes represent different molecular control points. Receptors can influence downstream signaling, enzymes regulate biochemical reactions, ion channels affect cellular ion movement, and nucleic acids provide information that can be acted upon by an intervention. Their distinct roles help determine how binding or modulation may change cell behavior and physiological function.
The outcome depends on the target’s role within the relevant disease mechanism and the surrounding cellular context. Altering one molecule or pathway may restore function in one setting but have a different consequence where signaling, target distribution, or disease biology differs. Studying these variables supports more precise therapeutic strategies across cancer, infection, neurological disease, and other conditions.
A research program can move from identifying a candidate molecule, pathway, or disease mechanism to validating its biological importance, then examining how an intervention changes activity and downstream effects. Researchers also consider target distribution and treatment resistance before selecting an appropriate development approach. The process connects molecular biology with drug discovery and supports development of small molecules, biologics, and other interventions.
Target distribution indicates where the intervention may act, while observed biological effects show whether that action changes physiology or disease-related processes in the intended direction. Considering both provides a stronger basis for interpreting therapeutic potential than examining molecular binding alone. These evaluations can also reveal information useful for biomarker development and more precise treatment selection.
Changes in target biology or in related disease mechanisms can influence whether a treatment continues to work, making resistance an important part of target study. Measuring target distribution and biological effects can also identify features associated with response. Such information supports biomarker development, which can help relate molecular characteristics to more precise therapeutic approaches in diseases including cancer.